Biomarkers for glioblastoma: MMP2 and NGAL.

Shehan, Jennifer N.; Gupta, Suprit; Rachagani, Satyanarayana; Zhang, Yan; Mallya, Kavita; Pai, Priya; Kaur, Sukhwinder; Jain, Maneesh; Kueh, Alice; White, Matthew L.; Aizenberg, Michele R.; McComb, Rodney D.; Smith, Lynette M.; Batra, Surinder K.; Shonka, Nicole

doi:10.1200/jco.2016.34.15_suppl.e13516

Cited by 3 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, very early changes (within 4 h to 2 days) in three biomarkers (CA9, collagen IV, and sVEGFR2) were associated with eventual disease outcome; however, these were excluded from this analysis given the inappropriately long time interval between such changes and response assessment. A second study evaluating MMP2 and the inflammatory response protein NGAL did not find differential expression in PsP vs. TP (60).…”

Section: Angiogenic and Inflammatory Signaling Moleculesmentioning

confidence: 86%

“…Forty-nine biomarkers within 15 studies were proteins related to angiogenic and inflammatory signaling cascades (Table A7) (47)(48)(49)(50)(51)(52)(53)(54)(55)(56)(57)(58)(59)(60)(61). The vast majority were detected using enzyme-linked immunosorbent assay (ELISA) or other immunoassay variants.…”

Section: Angiogenic and Inflammatory Signaling Moleculesmentioning

confidence: 99%

“…The vast majority were detected using enzyme-linked immunosorbent assay (ELISA) or other immunoassay variants. Ten of 15 studies reporting biomarkers in this category involved treatment with an antiangiogenic agent either alone or in combination with other agents (52)(53)(54)(55)(56)(57)(59)(60)(61). Antiangiogenic agents used in identified studies were bevacizumab, cediranib [a VEGF receptor (VEGFR) inhibitor], aflibercept [a VEGF and placental growth factor (PIGF) decoy receptor], vorinostat (a histone deacetylase inhibitor with antiangiogenic properties) and vandetanib (a VEGFR inhibitor).…”

Section: Angiogenic and Inflammatory Signaling Moleculesmentioning

confidence: 99%

See 2 more Smart Citations

Blood Biomarkers of Glioma in Response Assessment Including Pseudoprogression and Other Treatment Effects: A Systematic Review

et al. 2020

View full text Add to dashboard Cite

Imaging-based monitoring of disease burden in glioma patients is frequently confounded by treatment effects. Circulating biomarkers could theoretically augment imaging-based response monitoring. This systematic review aimed to present and evaluate evidence for differential expression and diagnostic accuracy of circulating biomarkers with respect to outcomes of tumor response, progression, stable disease, and treatment effects (pseudoprogression, radionecrosis, pseudoresponse, and pseudolesions) in patients undergoing treatment for World Health Organization grades II-IV diffuse astrocytic and oligodendroglial tumors. MEDLINE, EMBASE, Web Of Science, and SCOPUS databases were searched until August 18, 2019, for observational or diagnostic studies on multiple circulating biomarker types: extracellular vesicles, circulating nucleic acids, circulating tumor cells, circulating proteins, and metabolites, angiogenesis related cells, immune cells, and other cell lines. Methodological quality of included studies was assessed using an adapted Quality Assessment of Diagnostic Accuracy Studies-2 tool, and level of evidence (IA-IVD) for individual biomarkers was evaluated using an adapted framework from the National Comprehensive Cancer Network guidelines on evaluating tumor marker utility. Of 13,202 unique records, 58 studies met the inclusion criteria. One hundred thirty-three distinct biomarkers were identified in a total of 1,853 patients across various treatment modalities. Fifteen markers for response, progression, or stable disease and five markers for pseudoprogression or radionecrosis reached level IB. No biomarkers reached level IA. Only five studies contained data for diagnostic accuracy measures. Overall methodological quality of included studies was low. While extensive data on biomarker dysregulation in varying response categories were reported, no biomarkers ready for clinical application were identified. Further assay refinement and evaluation in larger cohorts with diagnostic accuracy study designs are required.

show abstract

Section: Angiogenic and Inflammatory Signaling Moleculesmentioning

confidence: 86%

Section: Angiogenic and Inflammatory Signaling Moleculesmentioning

confidence: 99%

Section: Angiogenic and Inflammatory Signaling Moleculesmentioning

confidence: 99%

See 1 more Smart Citation

Blood Biomarkers of Glioma in Response Assessment Including Pseudoprogression and Other Treatment Effects: A Systematic Review

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Elevated expression levels of proteins (e.g., MMP-2 and MMP-9) have frequently been developed as triggering signals for cancer therapy 178,179 . The MMP-2-activated shrinkable nanoarchitecture is constructed for the precise delivery of anticancer drugs 180 .…”

Section: Protein-responsivementioning

confidence: 99%

Pore-engineered nanoarchitectonics for cancer therapy

Sutrisno

Ariga

2023

NPG Asia Mater

View full text Add to dashboard Cite

Nanoarchitectonics describes the integration of nanotechnology with other fields as a postnanotechnology concept that elevates it to material science. Based on this fundamental principle, we address pore-engineered nanoarchitectonics with application targets for cancer therapy by combining basic descriptions and exemplifying therapy applications in this review. The initial two sections briefly summarize pore-engineered nanoarchitectonics basics according to classification based on (i) material porosity and (ii) material composition. Afterward, the main application-oriented section—designing mesoporous material for cancer therapy—is presented. Various types of drug delivery systems, including mesoporous nanoparticles as nanocarriers, endogenous stimuli-responsive drug delivery, exogenous stimuli-responsive drug delivery, and targeted drug delivery, are described. Importantly, the clinical translation of mesoporous materials is further discussed. Mesoporous materials are unique nanoparticles that offer a network of cavities as vehicles for drug nanocarriers. Regarding the developments that allow mesoporous nanoparticles to be broadly used in clinical settings, there are several challenges that should be solved for their clinical application. From a clinical perspective, there are tremendous processes in the development of mesoporous materials.

show abstract

“…DOX•HCl was encapsulated in the matrix metalloproteinase 2 (MMP-2) responsive peptideliposome (D@ML). 22−25 D@MLL was synthesized while the surface of D@ML was modified with lipoteichoic acid (LTA), 26 which binds to monocytes via the CD14 receptor (Scheme 1A). First, low-dose RT in the tumor sites induced TAMs M1-type polarization and increased CCL-2 expression (Scheme 1B).…”

Section: Introductionmentioning

confidence: 99%

Nanoparticles Hitchhike on Monocytes for Glioblastoma Treatment after Low-Dose Radiotherapy

et al. 2023

View full text Add to dashboard Cite

Glioblastomas (GBMs) are aggressive primary brain tumors with fatal outcome. Traditional chemo-radiotherapy has poor therapeutic effect and significant side effects, due to the drug and radiotherapy (RT) resistance, natural blood-brain barrier, and high-dose RT damage. Even more, tumor-associated monocytes (macrophages and microglia, TAMs) constitute up to 30%–50% of the GBM cellular content, and the tumor microenvironment (TME) in GBM is extremely immunosuppressive. Here, we synthesized nanoparticles (D@MLL) that hitchhike on circulating monocytes to target intracranial GBMs with the assistance of low-dose RT. The chemical construction of D@MLL was DOX·HCl loaded MMP-2 peptide-liposome, which could target monocytes by the surface modified lipoteichoic acid. First, low-dose RT at the tumor site increases monocyte chemotaxis and induces M1 type polarization of TAMs. Subsequently, the intravenous injected D@MLL targets circulating monocytes and hitchhikes with them to the central site of the GBM area. DOX·HCl was then released by the MMP-2 response, inducing immunogenic cell death, releasing calreticulin and high-mobility group box 1. This further contributed to TAMs M1-type polarization, dendritic cell maturation, and T cell activation. This study demonstrates the therapeutic advantages of D@MLL delivered by endogenous monocytes to GBM sites after low-dose RT, and it provides a high-precision treatment for GBMs.

show abstract

Biomarkers for glioblastoma: MMP2 and NGAL.

Cited by 3 publications

References 0 publications

Blood Biomarkers of Glioma in Response Assessment Including Pseudoprogression and Other Treatment Effects: A Systematic Review

Blood Biomarkers of Glioma in Response Assessment Including Pseudoprogression and Other Treatment Effects: A Systematic Review

Pore-engineered nanoarchitectonics for cancer therapy

Nanoparticles Hitchhike on Monocytes for Glioblastoma Treatment after Low-Dose Radiotherapy

Contact Info

Product

Resources

About